ArticleFrontiers in cell and developmental biology2026
Stage-specific disruption of erythropoiesis leads to anemia in newly diagnosed multiple myeloma patients.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple myeloma (MM) associated anemia affects over 60% of patients and correlates with poor prognosis. While most studies focus on the impact of microenvironment on erythropoiesis in MM, the stage-specific erythroid cell defects and their underlying molecular mechanisms remain poorly characterized. Method: Clinical data were collected from 300 patients with newly diagnosed multiple myeloma (NDMM) and 300 healthy controls. Phenotypic and transcriptomic profiles of bone marrow early and late erythropoiesis were compared between healthy donors (HDs) and NDMM patients with anemia (NDMM-A). Furthermore, in vitro erythroid culture assays were performed to verify the intrinsic erythropoietic impairments in NDMM-A patients. Results: Primary erythropoiesis profiles from bone marrow revealed a global reduction in erythroblasts across all maturation stages, along with significantly impaired colony-forming capacity of erythroid progenitors in NDMM patients. Transcriptomic profiling identified stage-specific dysregulation in the early and late erythropoiesis of NDMM-A patients. Erythroid progenitors exhibited downregulation of cell-cycle regulators (e.g., CDC20, AURKB) and key erythropoietic transcription factors (e.g., GATA1, GFI1B), accompanied by upregulation of immune-response genes (OAS3, OAS2). Conversely, terminal erythroblasts showed upregulation of genes involved in oxidative phosphorylation and the p53 pathway. In vitro assays confirmed intrinsic defects in erythroblasts derived from NDMM patients' CD34+ cells, including poor proliferation, increased apoptosis rate, and defective enucleation. Conclusion: These findings demonstrate that both cell-intrinsic impairments and external responses drive stage-specific erythropoietic failure in NDMM, providing new insights for therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.